Drug Profile
Research programme: complement inhibitors - Amyndas Pharmaceuticals
Alternative Names: AMANDEN; AMY 201; AMY-112; Compsorbin; Compstatin analogues - Amyndas; Cp 40Latest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Amyndas Pharmaceuticals
- Class Peptides
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 01 Mar 2023 Preclinical development is ongoing in Age-related-macular-degeneration in USA
- 28 Nov 2021 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA
- 26 Oct 2017 Preclinical trials in Age-related macular degeneration in USA before October 2017 (Amyndas Pharmaceuticals website, October 2017)